<DOC>
	<DOCNO>NCT01811472</DOCNO>
	<brief_summary>The purpose study determine whether LCQ908 effectively lower liver fat , assess MRI ass safety tolerability profile subject non-alcoholic fatty liver disease ( NAFLD ) .</brief_summary>
	<brief_title>Study Assess Efficacy , Safety Tolerability LCQ908 NAFLD Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>History liver steatosis precede 24 month History fast TGs &gt; 200 mg/dL ( confirmed screening ) . Liver fat ≥ 10 % determined central MRI laboratory . Subjects follow medication include medication medically necessary , stop investigator feel dose remain stable duration doubleblind treatment period : 1 . Stable dose antidiabetic medication ( metformin and/or sulfonylurea ) least 8 week prior screen . 2 . Stable dose betablockers thiazide diuretic least 8 week prior screen . 3 . Stable dos fibrates , statin , niacin , ezetimibe least 8 week prior screen . 4 . Stable dose vitamin E patient take &gt; 200 IU/day least 6 month prior screen . Treatment omega3acid ethyl ester omega3polyunsaturated fatty acid ( PUFA ) contain supplement &gt; 200 mg per day within 8 week screen . Treatment antiretrovirals , tamoxifen , methotrexate , cyclophosphamide , isotretinoin , bile acid binding resins pharmacologic dos oral glucocorticoid ( ≥10 mg prednisone per day equivalent ) within 8 week screen . ALT AST &gt; 250 IU/L time screen . History/current evidence heavy alcohol use alcoholism ( &gt; 21 drink per week men &gt; 14 drink per week woman ) 2year period prior screen . Presence chronic liver disease , chronic hepatitis B and/or C , alcoholic liver disease , hemochromatosis , Wilson 's disease , know cirrhosis . Platelet count &lt; 150,000 screening . BMI &gt; 45 Kg/m2 . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Multi-center ,</keyword>
	<keyword>randomize ,</keyword>
	<keyword>double-blind ,</keyword>
	<keyword>NAFLD ,</keyword>
	<keyword>elevate triglyceride</keyword>
</DOC>